Ken Griffin Verastem, Inc. Call Options Transaction History

Citadel Advisors LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$0.39 - $0.71 $30,420 - $55,380	-78,000 Reduced 89.97%	8,700 $3,000
Q4 2022 Feb 14, 2023	SELL	$0.33 - $10.44 $297 - $9,396	-900 Reduced 1.03%	86,700 $34,000
Q3 2022 Nov 14, 2022	SELL	$0.92 - $11.16 $47,380 - $574,740	-51,500 Reduced 37.02%	87,600 $74,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $838M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.